Business● LowOct 30 · Oct 30, 2026, 2:50 PM
Alnylam downgraded at Bernstein on TRITON-CM trial design
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Alnylam's stock has been downgraded by Bernstein, citing concerns about the TRITON-CM trial design. This indicates a potential negative outlook for the company based on its clinical trial strategy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business31m agoWith the Pope's visit, business leaders call for a broad dialogue table with the Government and workersClarínBusiness51m agoAba South establishes commercial farms to boost revenue, create jobsVanguard NigeriaBusiness1h ago"Forever cruise" arrested at Singapore port, court records showCBS NewsBusiness1h agoShort week in the markets: the Government faces a key round, after sharp drops in bonds and sharesClarín